对化疗药物和生物制剂脱敏的最新进展。

IF 4.7 2区医学 Q1 ALLERGY

Annals of Allergy Asthma & Immunology Pub Date : 2025-10-01 DOI:10.1016/j.anai.2025.07.018

Joana Caiado MD, PhD , Mariana C. Castells MD, PhD

{"title":"对化疗药物和生物制剂脱敏的最新进展。","authors":"Joana Caiado MD, PhD , Mariana C. Castells MD, PhD","doi":"10.1016/j.anai.2025.07.018","DOIUrl":null,"url":null,"abstract":"<div><div>Hypersensitivity reactions to chemotherapeutics and biologicals are increasing, which can affect the prognosis of the underlying disease. Purpose of review: The goal of this review is to provide recent advancements in the diagnosis and management of hypersensitivity reactions based on current data. Recent findings: Multiple studies have provided evidence of the safety and efficacy of rapid drug desensitizations. The knowledge of recently described phenotypes (type I, cytokine release syndrome, and mixed reactions) and current biomarkers (tryptase, interleukin-6, skin testing, basophil activation, and specific IgE) allows a correct risk stratification, critical to guide the desensitization planning. Personalized protocols and premedications have been successfully used to decrease the number and severity of breakthrough reactions. Summary: Rapid drug desensitization allows patients to be treated with best therapies, increasing the quality of life and life expectancy.</div></div>","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":"135 4","pages":"Pages 374-382"},"PeriodicalIF":4.7000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Update on desensitization to chemotherapeutics and biologicals\",\"authors\":\"Joana Caiado MD, PhD , Mariana C. Castells MD, PhD\",\"doi\":\"10.1016/j.anai.2025.07.018\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Hypersensitivity reactions to chemotherapeutics and biologicals are increasing, which can affect the prognosis of the underlying disease. Purpose of review: The goal of this review is to provide recent advancements in the diagnosis and management of hypersensitivity reactions based on current data. Recent findings: Multiple studies have provided evidence of the safety and efficacy of rapid drug desensitizations. The knowledge of recently described phenotypes (type I, cytokine release syndrome, and mixed reactions) and current biomarkers (tryptase, interleukin-6, skin testing, basophil activation, and specific IgE) allows a correct risk stratification, critical to guide the desensitization planning. Personalized protocols and premedications have been successfully used to decrease the number and severity of breakthrough reactions. Summary: Rapid drug desensitization allows patients to be treated with best therapies, increasing the quality of life and life expectancy.</div></div>\",\"PeriodicalId\":50773,\"journal\":{\"name\":\"Annals of Allergy Asthma & Immunology\",\"volume\":\"135 4\",\"pages\":\"Pages 374-382\"},\"PeriodicalIF\":4.7000,\"publicationDate\":\"2025-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annals of Allergy Asthma & Immunology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1081120625003722\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ALLERGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Allergy Asthma & Immunology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1081120625003722","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ALLERGY","Score":null,"Total":0}

引用次数: 0

摘要

对化疗药物和生物制剂的超敏反应（HSRs）正在增加，这可能影响潜在疾病的预后。综述目的：本综述的目的是根据现有数据提供HSRs诊断和管理的最新进展。近期发现：多项研究已经提供了快速药物脱敏（RDD）安全性和有效性的证据。最近描述的表型（I型，细胞因子释放综合征和混合反应）和当前的生物标志物（胰蛋白酶，IL-6，皮肤测试，嗜碱性粒细胞激活和特异性IgE）的知识允许正确的风险分层，对指导脱敏计划至关重要。个性化方案和预用药已成功地用于减少突破性反应的数量和严重程度。总结：RDD允许患者接受最佳治疗，提高生活质量和预期寿命。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Update on desensitization to chemotherapeutics and biologicals

Hypersensitivity reactions to chemotherapeutics and biologicals are increasing, which can affect the prognosis of the underlying disease. Purpose of review: The goal of this review is to provide recent advancements in the diagnosis and management of hypersensitivity reactions based on current data. Recent findings: Multiple studies have provided evidence of the safety and efficacy of rapid drug desensitizations. The knowledge of recently described phenotypes (type I, cytokine release syndrome, and mixed reactions) and current biomarkers (tryptase, interleukin-6, skin testing, basophil activation, and specific IgE) allows a correct risk stratification, critical to guide the desensitization planning. Personalized protocols and premedications have been successfully used to decrease the number and severity of breakthrough reactions. Summary: Rapid drug desensitization allows patients to be treated with best therapies, increasing the quality of life and life expectancy.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Annals of Allergy Asthma & Immunology 医学-过敏

CiteScore

6.50

自引率

6.80%

发文量

437

审稿时长

33 days

期刊介绍： Annals of Allergy, Asthma & Immunology is a scholarly medical journal published monthly by the American College of Allergy, Asthma & Immunology. The purpose of Annals is to serve as an objective evidence-based forum for the allergy/immunology specialist to keep up to date on current clinical science (both research and practice-based) in the fields of allergy, asthma, and immunology. The emphasis of the journal will be to provide clinical and research information that is readily applicable to both the clinician and the researcher. Each issue of the Annals shall also provide opportunities to participate in accredited continuing medical education activities to enhance overall clinical proficiency.